Q1 Earnings Forecast for SXTP Issued By HC Wainwright

60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP) – Research analysts at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for shares of 60 Degrees Pharmaceuticals in a note issued to investors on Tuesday, February 25th. HC Wainwright analyst E. White anticipates that the company will earn ($2.81) per share for the quarter. HC Wainwright has a “Neutral” rating on the stock. The consensus estimate for 60 Degrees Pharmaceuticals’ current full-year earnings is ($5.09) per share. HC Wainwright also issued estimates for 60 Degrees Pharmaceuticals’ Q2 2025 earnings at ($1.18) EPS, Q3 2025 earnings at ($0.74) EPS and Q4 2025 earnings at ($0.53) EPS.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of 60 Degrees Pharmaceuticals in a research note on Wednesday, February 19th.

60 Degrees Pharmaceuticals Trading Down 9.4 %

Shares of SXTP stock opened at $1.92 on Wednesday. 60 Degrees Pharmaceuticals has a twelve month low of $1.78 and a twelve month high of $35.99. The company’s 50-day moving average price is $0.97 and its 200-day moving average price is $1.13. The stock has a market cap of $14.14 million, a price-to-earnings ratio of -0.19 and a beta of 4.22.

Insider Buying and Selling

In other 60 Degrees Pharmaceuticals news, CEO Geoffrey S. Dow purchased 7,164 shares of the firm’s stock in a transaction dated Monday, December 9th. The shares were acquired at an average price of $6.35 per share, with a total value of $45,491.40. Following the purchase, the chief executive officer now directly owns 18,916 shares in the company, valued at approximately $120,116.60. This trade represents a 60.96 % increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website. Over the last three months, insiders acquired 12,073 shares of company stock worth $76,966. Company insiders own 10.27% of the company’s stock.

60 Degrees Pharmaceuticals Company Profile

60 Degrees Pharmaceuticals, Inc, a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue.